Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zheng, D ^a,c   Ye, X ^b   Zhang, M Z ^b   Sun, Y ^b   Wang, J Y ^a,c   Ni, J ^a,c   Zhang, H P ^a,c   Zhang, L ^a,c   Luo, J ^a,c   Zhang, J ^a,c   Tang, L ^a,c   Su, B ^a,c   Chen, G ^a,c   Zhu, G ^b,d   Gu, Y ^b   Xu, J F ^a,c  

^a TONGJI UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

^c SHANGHAI PULMONARY HOSPITAL   (China)

^d Amoy Diagnostics Co LTD   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84958569032     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20913     Document Type: Article

References (40)

1. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-957 (2009).
2. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388 (2010).
3. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations ofthe epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol 11, 121-128 (2010).
4. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239-246 (2012).
5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced. Lancet Oncol 12, 735-742 (2011).
6. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346, 92-98 (2002).
7. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355, 2542-2550 (2006).
8. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005).
9. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Plos Med 2, e73 (2005).
10. Balak, M. N. et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12, 6494-6501 (2006).
11. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104, 20932-20937 (2007).
12. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
13. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26 (2011).
14. Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109, E2127-2133 (2012).
15. Zakowski, M. F., Ladanyi, M. & Kris, M. G., Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355, 213-215 (2006).
16. Aparicio, S. & Caldas, C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 368, 842-851 (2013).
17. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883-892 (2012).
18. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
19. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
20. Leary, R. J. et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4, 162ra154 (2012).
21. Chan, K. C. et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59, 211-224 (2013).
22. Punnoose, E. A. et al. Evaluation of circulating tumor cells and circulating tumor dna in non-small cell lung cancer: association with clinical endpoints in a phase ii clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18, 2391-2401 (2012).
23. Luo, J., Shen, L. & Zheng, D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 4, 6269 (2014).
24. Kuang, Y. et al. Noninvasive detection of egfr t790m in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15, 2630-2636 (2009).
25. Sakai, K. et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 104, 1198-1204 (2013).
26. Maheswaran, S. et al. Detection of mutations in egfr in circulating lung-cancer cells. N Engl J Med 359, 366-377 (2008).
27. Sorensen, B. S. et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120, 3896-3901 (2014).
28. Oxnard, G. R. et al. noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698-1705 (2014).
29. Zhu, G. et al. Highly sensitive droplet digital pcr method for detection of egfr-activating mutations in plasma cell-free dna from patients with advanced non-small cell lung cancer. J Mol Diagn 17, 265-272 (2015).
30. Oxnard, G. R. et al. Acquired resistance to egfr tyrosine kinase inhibitors in egfr-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17, 1616-1622 (2011).
31. Hata, A. et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer 119, 4325-4332 (2013).
32. Li, W. et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 84, 295-300 (2014).
33. Kosaka, T. et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12, 5764-5769 (2006).
34. Chen, H. J. et al. Clinicopathologic and molecular features of epidermal growth factor receptor t790m mutation and c-MET amplification in tyrosine kinase inhibitor-resistant chinese non-small cell lung cancer. Pathol Oncol Res 15, 651-658 (2009).
35. Chmielecki, J.et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3, 90ra59 (2011).
36. Lee, Y. et al. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer 120, 2090-2098 (2014).
37. Mok, T. S. et al. Detection and dynamic changes of egfr mutations from circulating tumor dna as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21, 3196-3203 (2015).
38. Graziano, P. et al. EGFR-driven behavior and intrapatient T790M mutation heterogeneity of non-small-cell carcinoma with squamous histology. J Clin Oncol 33, e115-e118 (2015)
39. Zofia, P. et al. Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one postresistant biopsy. J Clin Oncol 32, 5s(suppl; abstr 8053) (2014).
40. Jackman, D. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. J Clin Oncol 28, 357-360 (2010).